TD Asset Management Inc Purchases Shares of 36,132 Perrigo Company plc $PRGO

TD Asset Management Inc acquired a new stake in shares of Perrigo Company plc (NYSE:PRGO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 36,132 shares of the company’s stock, valued at approximately $965,000.

Several other large investors have also recently made changes to their positions in PRGO. Price T Rowe Associates Inc. MD lifted its position in shares of Perrigo by 41.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 11,073,026 shares of the company’s stock worth $310,488,000 after buying an additional 3,227,487 shares in the last quarter. Millennium Management LLC increased its stake in Perrigo by 5,198.0% in the 1st quarter. Millennium Management LLC now owns 2,052,599 shares of the company’s stock worth $57,555,000 after acquiring an additional 2,013,856 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Perrigo by 126.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock worth $32,520,000 after acquiring an additional 647,982 shares during the last quarter. Bahl & Gaynor Inc. raised its holdings in shares of Perrigo by 40.7% during the 1st quarter. Bahl & Gaynor Inc. now owns 2,146,352 shares of the company’s stock worth $60,184,000 after acquiring an additional 621,155 shares in the last quarter. Finally, Sound Shore Management Inc. CT boosted its position in shares of Perrigo by 23.1% during the 1st quarter. Sound Shore Management Inc. CT now owns 3,285,167 shares of the company’s stock valued at $92,116,000 after acquiring an additional 616,387 shares during the last quarter. 95.91% of the stock is owned by institutional investors.

Perrigo Stock Performance

Shares of NYSE:PRGO opened at $21.67 on Thursday. The company has a market capitalization of $2.98 billion, a price-to-earnings ratio of -37.35 and a beta of 0.43. Perrigo Company plc has a 12 month low of $20.51 and a 12 month high of $30.93. The firm’s 50-day moving average is $22.31 and its 200 day moving average is $24.88. The company has a current ratio of 2.32, a quick ratio of 1.24 and a debt-to-equity ratio of 0.81.

Perrigo (NYSE:PRGO) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.57 EPS for the quarter, missing the consensus estimate of $0.59 by ($0.02). The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.08 billion. Perrigo had a negative net margin of 1.86% and a positive return on equity of 9.09%. The business’s revenue for the quarter was down .9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.53 earnings per share. Research analysts predict that Perrigo Company plc will post 2.56 EPS for the current year.

Perrigo Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 16th. Investors of record on Friday, August 29th were issued a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a yield of 5.4%. The ex-dividend date was Friday, August 29th. Perrigo’s dividend payout ratio is presently -200.00%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Wall Street Zen cut shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Saturday, October 18th. JPMorgan Chase & Co. reduced their target price on shares of Perrigo from $38.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, August 7th. Canaccord Genuity Group decreased their target price on shares of Perrigo from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Perrigo in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $34.00.

Insider Activity

In other news, Director Geoffrey M. Parker purchased 4,375 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The shares were bought at an average cost of $22.97 per share, for a total transaction of $100,493.75. Following the acquisition, the director owned 33,287 shares of the company’s stock, valued at approximately $764,602.39. This trade represents a 15.13% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Abigail Lennox purchased 1,255 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The shares were purchased at an average price of $22.41 per share, for a total transaction of $28,124.55. Following the completion of the acquisition, the executive vice president directly owned 1,255 shares in the company, valued at $28,124.55. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 10,118 shares of company stock valued at $232,699. 0.70% of the stock is currently owned by company insiders.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.